SML3353
GSK943
≥98% (HPLC)
别名:
(2R,3R)-N5-((1R,5S,6r)-3-oxabicyclo[3.1.0]hexan-6-yl)-2-(fluoromethyl)-N7-methyl-3-phenyl-2,3-dihydrobenzofuran-5,7-dicarboxamide
质量水平
方案
≥98% (HPLC)
表单
powder
颜色
white to beige
溶解性
DMSO: 2 mg/mL, clear
储存温度
2-8°C
SMILES字符串
CNC(C1=C2C([C@](C3=CC=CC=C3)([H])[C@@H](O2)CF)=CC(C(N[C@@H]4[C@]5([H])[C@@]4([H])COC5)=O)=C1)=O
InChI key
WZQLVEPIBAOOGF-PXTPFGJHSA-N
生化/生理作用
Inactive (2R,3R) stereoisomer of and the recommended negative control for the potent and selective pan-second bromodomain (BD2) inhibitor GSK973.
GSK943 corresponds to the inactive (2R,3R) stereoisomer of and the recommended negative control for the potent and selective pan-second bromodomain (BD2) inhibitor GSK973.
GSK943 corresponds to the inactive (2R,3R) stereoisomer of and the recommended negative control for the potent and selective pan-second bromodomain (BD2) inhibitor GSK973.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
此项目有
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
Alex Preston et al.
ACS medicinal chemistry letters, 11(8), 1581-1587 (2020-08-25)
Pan-BET inhibitors have shown profound efficacy in a number of in vivo preclinical models and have entered the clinic in oncology trials where adverse events have been reported. These inhibitors interact equipotently with the eight bromodomains of the BET family
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持